{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:30:03Z","timestamp":1784673003528,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.7759\/cureus.65866","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T18:04:05Z","timestamp":1722449045000},"source":"Crossref","is-referenced-by-count":8,"title":["The Emerging Role of Neurosteroids: Novel Drugs Brexanalone, Sepranolone, Zuranolone, and Ganaxolone in Mood and Neurological Disorders"],"prefix":"10.7759","author":[{"given":"Malay","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajpat","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2022.100367","article-title":"Neurosteroids and early-life programming: an updated perspective","volume":"25","author":"Sze Y","year":"2022","unstructured":"Sze Y, Brunton PJ. Neurosteroids and early-life programming: an updated perspective. Curr Opin Endocr Metab Res. 2022, 25:100367. 10.1016\/j.coemr.2022.100367","journal-title":"Curr Opin Endocr Metab Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32833735cf","article-title":"Neurosteroids and epilepsy","volume":"23","author":"Biagini G","year":"2010","unstructured":"Biagini G, Panuccio G, Avoli M. Neurosteroids and epilepsy. Curr Opin Neurol. 2010, 23:170-6. 10.1097\/WCO.0b013e32833735cf","journal-title":"Curr Opin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.81.125","article-title":"Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities","volume":"81","author":"Maurice T","year":"1999","unstructured":"Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol. 1999, 81:125-55. 10.1254\/jjp.81.125","journal-title":"Jpn J Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy DS","year":"2010","unstructured":"Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res. 2010, 186:113-37. 10.1016\/B978-0-444-53630-3.00008-7","journal-title":"Prog Brain Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2019.100788","article-title":"Neurosteroids as regulators of neuroinflammation","volume":"55","author":"Yilmaz C","year":"2019","unstructured":"Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, Alexaki VI. Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol. 2019, 55:100788. 10.1016\/j.yfrne.2019.100788","journal-title":"Front Neuroendocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2018.1476484","article-title":"Progesterone and human cognition","volume":"21","author":"Henderson VW","year":"2018","unstructured":"Henderson VW. Progesterone and human cognition. Climacteric. 2018, 21:333-40. 10.1080\/13697137.2018.1476484","journal-title":"Climacteric"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115495","article-title":"The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD","volume":"22","author":"Almeida FB","year":"2021","unstructured":"Almeida FB, Pinna G, Barros HM. The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD. Int J Mol Sci. 2021, 22:10.3390\/ijms22115495","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-3991-1","article-title":"DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action","author":"Ben Dor R","year":"2015","unstructured":"Ben Dor R, Marx CE, Shampine LJ, Rubinow DR, Schmidt PJ. DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. 2015. 10.1007\/s00213-015-3991-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.79","article-title":"DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli","volume":"38","author":"Sripada RK","year":"2013","unstructured":"Sripada RK, Marx CE, King AP, Rajaram N, Garfinkel SN, Abelson JL, Liberzon I. DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli. Neuropsychopharmacology. 2013, 38:1798-807. 10.1038\/npp.2013.79","journal-title":"Neuropsychopharmacology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951990","article-title":"Editorial: recent progress and perspectives in neurosteroid research","volume":"13","author":"Vaudry H","year":"2022","unstructured":"Vaudry H, Ubuka T, Soma KK, Tsutsui K. Editorial: recent progress and perspectives in neurosteroid research. Front Endocrinol (Lausanne). 2022, 13:951990. 10.3389\/fendo.2022.951990","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2435457100","article-title":"Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors","volume":"100","author":"Stell BM","year":"2003","unstructured":"Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci U S A. 2003, 100:14439-44. 10.1073\/pnas.2435457100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.03.004","article-title":"Mechanisms of neurosteroid interactions with GABA(A) receptors","volume":"116","author":"Akk G","year":"2007","unstructured":"Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. Mechanisms of neurosteroid interactions with GABA(A) receptors. Pharmacol Ther. 2007, 116:35-57. 10.1016\/j.pharmthera.2007.03.004","journal-title":"Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2004.066571","article-title":"Neuroactive steroids have multiple actions to potentiate GABAA receptors","volume":"558","author":"Akk G","year":"2004","unstructured":"Akk G, Bracamontes JR, Covey DF, Evers A, Dao T, Steinbach JH. Neuroactive steroids have multiple actions to potentiate GABAA receptors. J Physiol. 2004, 558:59-74. 10.1113\/jphysiol.2004.066571","journal-title":"J Physiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1399-04.2004","article-title":"Slow actions of neuroactive steroids at GABAA receptors","volume":"24","author":"Shu HJ","year":"2004","unstructured":"Shu HJ, Eisenman LN, Jinadasa D, Covey DF, Zorumski CF, Mennerick S. Slow actions of neuroactive steroids at GABAA receptors. J Neurosci. 2004, 24:6667-75. 10.1523\/JNEUROSCI.1399-04.2004","journal-title":"J Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABA(A) receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit A","year":"2021","unstructured":"Ghit A, Assal D, Al-Shami AS, Hussein DE. GABA(A) receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021, 19:123. 10.1186\/s43141-021-00224-0","journal-title":"J Genet Eng Biotechnol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113700","article-title":"Unravelling biological roles and mechanisms of GABA(B)R on addiction and depression through mood and memory disorders","volume":"155","author":"Wang YS","year":"2022","unstructured":"Wang YS, Qiu TY, Fu Q, et al.. Unravelling biological roles and mechanisms of GABA(B)R on addiction and depression through mood and memory disorders. Biomed Pharmacother. 2022, 155:113700. 10.1016\/j.biopha.2022.113700","journal-title":"Biomed Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000059","article-title":"Second messenger\/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder","volume":"18","author":"Niciu MJ","year":"2013","unstructured":"Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr. Second messenger\/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr. 2013, 18:231-41. 10.1017\/S1092852913000059","journal-title":"CNS Spectr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.02.052","article-title":"Altered GABA(A) receptor expression during epileptogenesis","volume":"497","author":"Gonz\u00e1lez MI","year":"2011","unstructured":"Gonz\u00e1lez MI, Brooks-Kayal A. Altered GABA(A) receptor expression during epileptogenesis. Neurosci Lett. 2011, 497:218-22. 10.1016\/j.neulet.2011.02.052","journal-title":"Neurosci Lett"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4149\/gpb_2011_03_310","article-title":"Functional changes in the septal GABAergic system of animals with a model of temporal lobe epilepsy","volume":"30","author":"Malkov AE","year":"2011","unstructured":"Malkov AE, Popova IY. Functional changes in the septal GABAergic system of animals with a model of temporal lobe epilepsy. Gen Physiol Biophys. 2011, 30:310-20. 10.4149\/gpb_2011_03_310","journal-title":"Gen Physiol Biophys"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13129","article-title":"The fate of interneurons, GABA(A) receptor sub-types and perineuronal nets in Alzheimer's disease","volume":"33","author":"Ali AB","year":"2023","unstructured":"Ali AB, Islam A, Constanti A. The fate of interneurons, GABA(A) receptor sub-types and perineuronal nets in Alzheimer's disease. Brain Pathol. 2023, 33:e13129. 10.1111\/bpa.13129","journal-title":"Brain Pathol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes S","year":"2017","unstructured":"Kanes S, Colquhoun H, Gunduz-Bruce H, et al.. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017, 390:480-89. 10.1016\/S0140-6736(17)31264-3","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.143","article-title":"Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program","volume":"320","author":"Epperson CN","year":"2023","unstructured":"Epperson CN, Rubinow DR, Meltzer-Brody S, et al.. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord. 2023, 320:353-9. 10.1016\/j.jad.2022.09.143","journal-title":"J Affect Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00672-w","article-title":"Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression","volume":"33","author":"Cooper MC","year":"2019","unstructured":"Cooper MC, Kilvert HS, Hodgkins P, Roskell NS, Eldar-Lissai A. Using matching-adjusted indirect comparisons and network meta-analyses to compare efficacy of brexanolone injection with selective serotonin reuptake inhibitors for treating postpartum depression. CNS Drugs. 2019, 33:1039-52. 10.1007\/s40263-019-00672-w","journal-title":"CNS Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression","volume":"32","author":"Kanes SJ","year":"2017","unstructured":"Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol. 2017, 32:10.1002\/hup.2576","journal-title":"Hum Psychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01155-w","article-title":"Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose","volume":"61","author":"Wald J","year":"2022","unstructured":"Wald J, Henningsson A, Hanze E, Hoffmann E, Li H, Colquhoun H, Deligiannidis KM. Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose. Clin Pharmacokinet. 2022, 61:1307-19. 10.1007\/s40262-022-01155-w","journal-title":"Clin Pharmacokinet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator","volume":"181","author":"Althaus AL","year":"2020","unstructured":"Althaus AL, Ackley MA, Belfort GM, et al.. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology. 2020, 181:108333. 10.1016\/j.neuropharm.2020.108333","journal-title":"Neuropharmacology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis KM","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al.. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021, 78:951-9. 10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14445","article-title":"Zuranolone in major depressive disorder: results from MOUNTAIN-A phase 3, multicenter, double-blind, randomized, placebo-controlled trial","volume":"84","author":"Clayton AH","year":"2023","unstructured":"Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ. Zuranolone in major depressive disorder: results from MOUNTAIN-A phase 3, multicenter, double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2023, 84:10.4088\/JCP.22m14445","journal-title":"J Clin Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.03.068","article-title":"Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder","volume":"308","author":"Suthoff E","year":"2022","unstructured":"Suthoff E, Kosinski M, Arnaud A, et al.. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. J Affect Disord. 2022, 308:19-26. 10.1016\/j.jad.2022.03.068","journal-title":"J Affect Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14475","article-title":"Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression","volume":"84","author":"Deligiannidis KM","year":"2023","unstructured":"Deligiannidis KM, Citrome L, Huang MY, et al.. Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression. J Clin Psychiatry. 2023, 84:10.4088\/JCP.22m14475","journal-title":"J Clin Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder","volume":"381","author":"Gunduz-Bruce H","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, et al.. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019, 381:903-11. 10.1056\/NEJMoa1815981","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2806","article-title":"A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults","volume":"37","author":"Bullock A","year":"2022","unstructured":"Bullock A, Gunduz-Bruce H, Zammit GK, et al.. A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol. 2022, 37:e2806. 10.1002\/hup.2806","journal-title":"Hum Psychopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105426","article-title":"A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder","volume":"133","author":"B\u00e4ckstr\u00f6m T","year":"2021","unstructured":"B\u00e4ckstr\u00f6m T, Ekberg K, Hirschberg AL, et al.. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021, 133:105426. 10.1016\/j.psyneuen.2021.105426","journal-title":"Psychoneuroendocrinology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2017.02.031","article-title":"Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial","volume":"80","author":"Bixo M","year":"2017","unstructured":"Bixo M, Ekberg K, Poromaa IS, et al.. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017, 80:46-55. 10.1016\/j.psyneuen.2017.02.031","journal-title":"Psychoneuroendocrinology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12887","article-title":"Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: a pilot study","volume":"81","author":"Dichtel LE","year":"2020","unstructured":"Dichtel LE, Nyer M, Dording C, et al.. Effects of open-label, adjunctive ganaxolone on persistent depression despite adequate antidepressant treatment in postmenopausal women: a pilot study. J Clin Psychiatry. 2020, 81:10.4088\/JCP.19m12887","journal-title":"J Clin Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder","volume":"234","author":"Rasmusson AM","year":"2017","unstructured":"Rasmusson AM, Marx CE, Jain S, et al.. A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology (Berl). 2017, 234:2245-57. 10.1007\/s00213-017-4649-y","journal-title":"Psychopharmacology (Berl)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17343","article-title":"Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial","volume":"63","author":"Vaitkevicius H","year":"2022","unstructured":"Vaitkevicius H, Ramsay RE, Swisher CB, Husain AM, Aimetti A, Gasior M. Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial. Epilepsia. 2022, 63:2381-91. 10.1111\/epi.17343","journal-title":"Epilepsia"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00324.x","article-title":"Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group","volume":"41","author":"Laxer K","year":"2000","unstructured":"Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, Monaghan EP. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia. 2000, 41:1187-94. 10.1111\/j.1528-1157.2000.tb00324.x","journal-title":"Epilepsia"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01182.x","article-title":"Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy","volume":"48","author":"Pieribone VA","year":"2007","unstructured":"Pieribone VA, Tsai J, Soufflet C, Rey E, Shaw K, Giller E, Dulac O. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007, 48:1870-4. 10.1111\/j.1528-1167.2007.01182.x","journal-title":"Epilepsia"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107112","article-title":"Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy","volume":"191","author":"Sullivan J","year":"2023","unstructured":"Sullivan J, Gunning B, Zafar M, et al.. Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy. Epilepsy Res. 2023, 191:107112. 10.1016\/j.eplepsyres.2023.107112","journal-title":"Epilepsy Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02514-2","article-title":"Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder","author":"Cutler AJ","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. 2023. 10.1038\/s41398-023-02514-2"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz333","article-title":"Brexanolone for postpartum depression","volume":"77","author":"Hutcherson TC","year":"2020","unstructured":"Hutcherson TC, Cieri-Hutcherson NE, Gosciak MF. Brexanolone for postpartum depression. Am J Health Syst Pharm. 2020, 77:336-45. 10.1093\/ajhp\/zxz333","journal-title":"Am J Health Syst Pharm"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020979627","article-title":"Brexanolone: a novel drug for the treatment of postpartum depression","volume":"35","author":"Patatanian E","year":"2022","unstructured":"Patatanian E, Nguyen DR. Brexanolone: a novel drug for the treatment of postpartum depression. J Pharm Pract. 2022, 35:431-6. 10.1177\/0897190020979627","journal-title":"J Pharm Pract"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105364","article-title":"Effects of paroxetine treatment and its withdrawal on neurosteroidogenesis","author":"Giatti S","year":"2021","unstructured":"Giatti S, Diviccaro S, Cioffi L, Falvo E, Caruso D, Melcangi RC. Effects of paroxetine treatment and its withdrawal on neurosteroidogenesis. 2021. 10.1016\/j.psyneuen.2021.105364"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/193104-the-emerging-role-of-neurosteroids-novel-drugs-brexanalone-sepranolone-zuranolone-and-ganaxolone-in-mood-and-neurological-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T18:04:08Z","timestamp":1722449048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/193104-the-emerging-role-of-neurosteroids-novel-drugs-brexanalone-sepranolone-zuranolone-and-ganaxolone-in-mood-and-neurological-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.65866","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}